NMB04
NMB04 is a recombinant anti-Human CD257 (BAFF) (BLyS) antibody. NMB04 binds with specificity and high affinity to soluble and membrane-bound Blys, and blocks Blys binding to receptors TACI, BCMA, and BR-3. NMB04 can be used for the research of autoimmune diseases.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human
NMB04 (1 h) binds to soluble human Blys with high affinity, as indicated by an EC50 of 0.023 nM[1].
NMB04 binds to soluble human Blys with a high sub-nanomolar affinity (KD = 7.38×10-10 M)[1].
NMB04 (1 h) binds to membrane-bound human Blys expressed on 293C18 cells with an EC50 of 0.13 nM[1].
NMB04 (1 h) potently inhibits Blys binding to human BR3, TACI, and BCMA receptors with IC50 values of 0.12 nM, 0.25 nM, and 0.12 nM respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| Species | Dose | Route | AUC0-∞ | T1/2 |
|---|---|---|---|---|
| Cynomolgus Monkey[1] | 5 mg/kg | i.v. | 17456 μg·h/mL | 153.83 h |
NMB04 (5 mg/kg; i.v.; once weekly; 4 weeks) inhibits CD20+ B cells in mesenteric lymph nodes and mature CD21+ B cells in peripheral blood in cynomolgus monkeys[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/C mice (female)[1]
-
Dosage:5 mg/kg
-
Administration:i.v.; on days 1 and 3
-
Result:Completely attenuated the increase in B220+/ThB+ mature splenic B cell population induced by human Blys.
Reduced the proportion of B220+/ThB+ cells to levels comparable to control group.
-
Animal Model:Cynomolgus Monkeys (2-4 years old, male)[1]
-
Dosage:5 mg/kg
-
Administration:i.v.; once weekly; 4 weeks
-
Result:Reduced the CD20+ B cell population in mesenteric lymph nodes to 18.31%.
Significantly inhibited the proliferation of mature CD21+ B cells in peripheral blood.
TNFSF13B/BAFF/CD257
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
NMB04 Related Classifications
HY-P992424 Related Classifications
Powered by Bioz